UGT1A1 Polymorphisms in Cancer: Impact on Irinotecan Treatment

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2017 Mar 11

PMID 28280378

Citations 41

Authors

Masashi Takano

Toru Sugiyama

Affiliations

Soon will be listed here.

Abstract

Mutations in the gene have been implicated in Gilbert syndrome, which shows mild hyperbilirubinemia, and a more aggressive childhood subtype, Crigler-Najjar syndrome. To date, more than 100 variants have been found in the gene. Among them, and have been reported to be associated with severe toxicities in patients treated with irinotecan-based chemotherapy by increasing the dose of SN-38 (7-ethyl-10-hydroxycamptothecin), an active form of irinotecan. Many association studies and meta-analyses have demonstrated the contribution of and polymorphisms to the toxicities caused by irinotecan-based therapy. The aim of this review was to evaluate the impact of these variants upon the toxicities and the efficacy of irinotecan-based chemotherapy.

Citing Articles

Allele frequency of genetic variations related to the gene-drug pair in a group of Iranian population.

Sarhangi N, Fahimfar N, Rouhollah F, Sharifi F, Bidkhori M, Nikfar S J Diabetes Metab Disord. 2024; 23(2):2279-2287.

PMID: 39610552 PMC: 11599689. DOI: 10.1007/s40200-024-01495-3.

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.

Wong M, Jones V, Yu W, Bosserman L, Lavasani S, Patel N Cancer Med. 2024; 13(16):e70096.

PMID: 39157928 PMC: 11331244. DOI: 10.1002/cam4.70096.

Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury.

Jiang J, Zhou Y, Zhong W, Luo L, Liu S, Xie X World J Gastroenterol. 2024; 30(9):1189-1212.

PMID: 38577195 PMC: 10989491. DOI: 10.3748/wjg.v30.i9.1189.

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.

Albadari N, Xie Y, Li W Front Pharmacol. 2024; 14:1340401.

PMID: 38269272 PMC: 10806212. DOI: 10.3389/fphar.2023.1340401.

A Comprehensive Bioinformatic Analysis of RNA-seq Datasets Reveals a Differential and Variable Expression of Wildtype and Variant UGT1A Transcripts in Human Tissues and Their Deregulation in Cancers.

Hu D, Marri S, Hulin J, McKinnon R, Mackenzie P, Meech R Cancers (Basel). 2024; 16(2).

PMID: 38254842 PMC: 10814044. DOI: 10.3390/cancers16020353.

References

Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M . Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011; 102(10):1868-73. DOI: 10.1111/j.1349-7006.2011.02030.x. View

Beutler E, Gelbart T, Demina A . Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A. 1998; 95(14):8170-4. PMC: 20948. DOI: 10.1073/pnas.95.14.8170. View

Udomuksorn W, Elliot D, Lewis B, Mackenzie P, Yoovathaworn K, Miners J . Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007; 17(12):1017-29. DOI: 10.1097/FPC.0b013e328256b1b6. View

Maruo Y, Nakahara S, Yanagi T, Nomura A, Mimura Y, Matsui K . Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol. 2015; 31(2):403-8. DOI: 10.1111/jgh.13071. View

Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K . Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009; 76(5):315-21. DOI: 10.1159/000209335. View

Kadakol A, Ghosh S, Sappal B, Sharma G, Chowdhury J, CHOWDHURY N . Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat. 2000; 16(4):297-306. DOI: 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z. View

Merali Z, Ross S, Pare G . The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact. 2014; 29(3):143-51. DOI: 10.1515/dmdi-2014-0009. View

Stintzing S, Modest D, Rossius L, Lerch M, Fischer von Weikersthal L, Decker T . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016; 17(10):1426-1434. DOI: 10.1016/S1470-2045(16)30269-8. View

Ferraldeschi R, Minchell L, Roberts S, Tobi S, Hadfield K, Blackhall F . UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009; 10(5):733-9. DOI: 10.2217/pgs.09.20. View

10.

Innocenti F, Kroetz D, Schuetz E, Dolan M, Ramirez J, Relling M . Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009; 27(16):2604-14. PMC: 2690389. DOI: 10.1200/JCO.2008.20.6300. View

11.

Braun M, Richman S, Thompson L, Daly C, Meade A, Adlard J . Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009; 27(33):5519-28. DOI: 10.1200/JCO.2008.21.6283. View

12.

McLeod H, Sargent D, Marsh S, Green E, King C, Fuchs C . Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010; 28(20):3227-33. PMC: 2903324. DOI: 10.1200/JCO.2009.21.7943. View

13.

Bosma P, van der Meer I, Bakker C, Hofman A, Paul-Abrahamse M, Witteman J . UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem. 2003; 49(7):1180-1. DOI: 10.1373/49.7.1180. View

14.

Martinez-Balibrea E, Abad A, Martinez-Cardus A, Gines A, Valladares M, Navarro M . UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer. 2010; 103(4):581-9. PMC: 2939780. DOI: 10.1038/sj.bjc.6605776. View

15.

Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M . Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos. 2004; 33(3):458-65. DOI: 10.1124/dmd.104.001800. View

16.

Iyer L, King C, Whitington P, Green M, Roy S, Tephly T . Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101(4):847-54. PMC: 508633. DOI: 10.1172/JCI915. View

17.

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y . Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015; 20(2):207-39. PMC: 4653248. DOI: 10.1007/s10147-015-0801-z. View

18.

Liu X, Cheng D, Kuang Q, Liu G, Xu W . Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2013; 14(2):120-9. PMC: 3992871. DOI: 10.1038/tpj.2013.10. View

19.

Lamas M, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y . The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemother Pharmacol. 2012; 69(6):1591-9. DOI: 10.1007/s00280-012-1866-2. View

20.

Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E . Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004; 10(15):5151-9. DOI: 10.1158/1078-0432.CCR-03-0548. View